Therapeutic Drug Monitoring of Infliximab in Jordanian Patients

Abstract

Background: Infliximab is a critical biologic therapy for severe inflammatory diseases, but its efficacy can be compromised by the development of anti-drug antibodies (ADAs). Therapeutic drug monitoring (TDM) is a recommended strategy to optimize treatment, but its implementation in Jordan has been limited. This study is the first to evaluate infliximab TDM in a Jordanian patient cohort. Methods: Seventy-three Jordanian patients with inflammatory bowel disease (IBD) were recruited for this study. Trough levels of infliximab and ADAs were measured using enzyme-linked immunosorbent assay (ELISA). Clinical and demographic data, including Erythrocyte Sedimentation Rate (ESR) and smoking status, were collected and analyzed. Results: A significant negative correlation was observed between infliximab trough levels and ADA levels (r = -0.69, p < 0.001). A notable 33.8% of patients developed high ADA titers (>100 ng/mL). ESR and smoking were significantly associated with lower infliximab levels and higher ADA levels. Other factors, such as hormones (Free T4, TSH), vitamins, and kidney and liver function tests, did not show significant correlations. Conclusion: This study provides the first evidence from Jordan supporting the utility of TDM for infliximab. The high prevalence of ADAs and their correlation with negative clinical outcomes underscore the need for routine TDM to guide dosing strategies and improve patient outcomes in Jordan. The findings also highlight ESR and smoking as potential risk factors for treatment failure.

Keywords

Supporting Institution

University of Petra

Project Number

7-4-2025

Ethical Statement

This study was done after obtaining approval from the Institutional Review Board (IRB#18363). All patients provided informed consent.

Thanks

The authors would like to thank Rahaf Sbaih and Leena Assi for their excellent clinical assistance. This project was funded by Petra University, under grant number 7-4-2025

References

  1. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, Macpherson A, Neurath MF, Ali RAR, Vavricka SR, Fiocchi C. Environmental triggers in IBD: A review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018; 15: 39-49. https://doi.org/10.1038/nrgastro.2017.136
  2. Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis. Nat Rev Dis Primers. 2020; 6: 74. https://doi.org/10.1038/s41572-020-0205-x
  3. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017; 389(10080): 1741-1755. https://doi.org/10.1016/S0140-6736(16)31711-1
  4. Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018; 16(1): 26-42. https://doi.org/10.5217/ir.2018.16.1.26
  5. Hossain M, Lordal AE, Olsson A, Storlahls S, Aleman M, Eberhardson R, Befrits S. Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance Infliximab treatment in inflammatory bowel disease. Scand J Gastroenterol. 2020; 55: 178-183. https://doi.org/10.1080/00365521.2020.1722738
  6. Xue JC, Hou XT, Zhao YW, Yuan S. Biological agents as attractive targets for inflammatory bowel disease therapeutics. Biochim Biophys Acta Mol Basis Dis. 2025; 1871(3): 167648. https://doi.org/10.1016/j.bbadis.2024.167648.
  7. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011; 33(9): 987-995. https://doi.org/10.1111/j.1365-2036.2011.04612.x
  8. Wong U, Cross RK. Primary and secondary nonresponse to Infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol. 2017; 13(10): 1039-1046. https://doi.org/10.1080/17425255.2017.1377180

Details

APA
Idkaidek, N., Hamadi, S., Abu-Qatouseh, L., Khalaf, H., Al-Hanahen, A., Mahli, A., Tuffaha, H., Alshoaibi, L., Quta, M., Ibrahim, M., Abualhaj, M., Tarawneh, A., Zinati, A., Qudah, M., Alqashash, R., Jibril, M., Al-Armouti, M., Ayesh, A., Aljhani, A., … Alshawahin, Z. (2026). Therapeutic Drug Monitoring of Infliximab in Jordanian Patients. Journal of Research in Pharmacy, 30(6), 1498-1506. https://doi.org/10.12991/jrespharm.1908394
AMA
1.Idkaidek N, Hamadi S, Abu-Qatouseh L, et al. Therapeutic Drug Monitoring of Infliximab in Jordanian Patients. J. Res. Pharm. 2026;30(6):1498-1506. doi:10.12991/jrespharm.1908394
Chicago
Idkaidek, Nasir, Salim Hamadi, Luay Abu-Qatouseh, et al. 2026. “Therapeutic Drug Monitoring of Infliximab in Jordanian Patients”. Journal of Research in Pharmacy 30 (6): 1498-1506. https://doi.org/10.12991/jrespharm.1908394.
EndNote
Idkaidek N, Hamadi S, Abu-Qatouseh L, Khalaf H, Al-Hanahen A, Mahli A, Tuffaha H, Alshoaibi L, Quta M, Ibrahim M, Abualhaj M, Tarawneh A, Zinati A, Qudah M, Alqashash R, Jibril M, Al-Armouti M, Ayesh A, Aljhani A, Abusaif K, Matahen M, Alshawahin Z (November 12, 2026) Therapeutic Drug Monitoring of Infliximab in Jordanian Patients. Journal of Research in Pharmacy 30 6 1498–1506.
IEEE
[1]N. Idkaidek et al., “Therapeutic Drug Monitoring of Infliximab in Jordanian Patients”, J. Res. Pharm., vol. 30, no. 6, pp. 1498–1506, Nov. 2026, doi: 10.12991/jrespharm.1908394.
ISNAD
Idkaidek, Nasir - Hamadi, Salim - Abu-Qatouseh, Luay - Khalaf, Hanaa - Al-Hanahen, Alaa - Mahli, Abdo - Tuffaha, Haya et al. “Therapeutic Drug Monitoring of Infliximab in Jordanian Patients”. Journal of Research in Pharmacy 30/6 (November 12, 2026): 1498-1506. https://doi.org/10.12991/jrespharm.1908394.
JAMA
1.Idkaidek N, Hamadi S, Abu-Qatouseh L, Khalaf H, Al-Hanahen A, Mahli A, Tuffaha H, Alshoaibi L, Quta M, Ibrahim M, Abualhaj M, Tarawneh A, Zinati A, Qudah M, Alqashash R, Jibril M, Al-Armouti M, Ayesh A, Aljhani A, Abusaif K, Matahen M, Alshawahin Z. Therapeutic Drug Monitoring of Infliximab in Jordanian Patients. J. Res. Pharm. 2026;30:1498–1506.
MLA
Idkaidek, Nasir, et al. “Therapeutic Drug Monitoring of Infliximab in Jordanian Patients”. Journal of Research in Pharmacy, vol. 30, no. 6, Nov. 2026, pp. 1498-06, doi:10.12991/jrespharm.1908394.
Vancouver
1.Nasir Idkaidek, Salim Hamadi, Luay Abu-Qatouseh, Hanaa Khalaf, Alaa Al-Hanahen, Abdo Mahli, Haya Tuffaha, Laith Alshoaibi, Mohammad Quta, Mohammad Ibrahim, Mahmoud Abualhaj, Aya Tarawneh, Asmaa Zinati, Moyad Qudah, Rola Alqashash, Motaz Jibril, Marwan Al-Armouti, Ahmad Ayesh, Aseel Aljhani, Karmen Abusaif, Maisa Matahen, Zaid Alshawahin. Therapeutic Drug Monitoring of Infliximab in Jordanian Patients. J. Res. Pharm. 2026 Nov. 12;30(6):1498-506. doi:10.12991/jrespharm.1908394